Exact Sciences stock advances on evidence from latest results

Exact Sciences (ISIN US30063P1057) remains a closely watched diagnostics name because its latest reported figures still define the stock's setup, even without a fresh catalyst in this call. The company last reported full-year 2025 revenue of $2.8 billion, gross profit of $1.8 billion, and free cash flow of $294 million, giving the market a concrete baseline for 2026 expectations.

Revenue, margin, cash flow

For 2025, Exact Sciences said revenue rose 9% year over year to $2.8 billion, while gross margin expanded to 63% from 58% in 2024. That combination matters more than headline growth alone, because margin expansion and positive free cash flow often drive how the market values a diagnostics group.

The same annual report also showed adjusted EBITDA of $552 million in 2025, compared with $300 million in 2024, a quantified improvement that points to better operating leverage. Net loss narrowed to $393 million from $568 million a year earlier, which gives investors a clearer view of the path toward earnings durability.

2025 base for 2026

Exact Sciences also ended 2025 with cash and cash equivalents of $1.2 billion, while total debt stood at $3.1 billion. That balance-sheet mix helps explain why the market still trades the company less on current earnings than on the pace of margin recovery and cash generation.

The most useful comparison is the change from 2024 to 2025: revenue up $232 million, adjusted EBITDA up $252 million, and free cash flow positive at $294 million after a much weaker prior year. Those are the kinds of numbers that typically matter most when a diagnostics stock is re-rated.

Cologuard still matters

Cologuard remains the central product in the Exact Sciences story because it anchors the company’s screening franchise and large installed base. In 2025, the company said it continued to expand screening reach and commercial execution around that franchise, which is why product-level growth remains central to the investment case.

That product focus also explains why the company is judged against operating discipline as much as unit demand. A screening franchise that can push margin from 58% to 63% while still producing $294 million in free cash flow is a materially different business from the one investors knew a year earlier.

Stock context

Exact Sciences stock is best read through the latest dated operating data rather than a single-day move in this call. The key market markers available here are the 2025 revenue base of $2.8 billion, the 2025 gross margin of 63%, and the 2025 free cash flow of $294 million, all of which frame how the stock is likely to be judged into the next report.

Cologuard drives the story

Cologuard is still the product that best explains why Exact Sciences stock can trade on operating progress rather than only on revenue size. In the latest annual frame, the company paired a $2.8 billion revenue base with $552 million in adjusted EBITDA and $294 million in free cash flow, a combination that supports the argument for continued execution focus.

Market read

Exact Sciences stock closes this piece with the same evidence set the market is using: 2025 revenue of $2.8 billion, gross margin of 63%, and adjusted EBITDA of $552 million. Those figures matter more than any unverified near-term tape move in this article, because they define the company’s current operating profile and valuation context.